EHP-102, also known as VCE-003.2, is a cannabinoid CB2 receptor agonist and PPARγ agonist which is under development for the treatment of Parkinson's disease and Huntington's disease. It is taken orally. The drug is a derivative of cannabigerol (CBG). It is under development by Emerald Health Sciences. As of February 2024, it is in the preclinical research stage of development for both Parkinson's disease and Huntington's disease, but no recent development has been reported for Huntington's disease.
See also List of investigational Parkinson's disease drugs
References